Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.
2.

AT1-receptor blockade with irbesartan improves peripheral but not coronary endothelial dysfunction in patients with stable coronary artery disease.

Warnholtz A, Ostad MA, Heitzer T, Thuneke F, Fröhlich M, Tschentscher P, Schwedhelm E, Böger R, Meinertz T, Munzel T.

Atherosclerosis. 2007 Oct;194(2):439-45. Epub 2006 Sep 12.

PMID:
16970950
3.

Effect of long-term irbesartan treatment on endothelium-dependent vasodilation in essential hypertensive patients.

Bragulat E, Larrousse M, Coca A, de la Sierra A.

Br J Biomed Sci. 2003;60(4):191-6.

PMID:
14725334
5.

Effect of combined treatment with alpha-Lipoic acid and acetyl-L-carnitine on vascular function and blood pressure in patients with coronary artery disease.

McMackin CJ, Widlansky ME, Hamburg NM, Huang AL, Weller S, Holbrook M, Gokce N, Hagen TM, Keaney JF Jr, Vita JA.

J Clin Hypertens (Greenwich). 2007 Apr;9(4):249-55.

6.

Treatment with irbesartan or atenolol improves endothelial function in essential hypertension.

von zur Mühlen B, Kahan T, Hägg A, Millgård J, Lind L.

J Hypertens. 2001 Oct;19(10):1813-8.

PMID:
11593101
7.

Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year follow-up in patients with essential hypertension.

Hirooka Y, Kimura Y, Sagara Y, Ito K, Sunagawa K.

Clin Exp Hypertens. 2008 Apr;30(3):267-76. doi: 10.1080/10641960802071000.

PMID:
18425706
8.

Angiotensin II receptor blockers improve endothelial dysfunction associated with sympathetic hyperactivity in metabolic syndrome.

Kishi T, Hirooka Y, Konno S, Sunagawa K.

J Hypertens. 2012 Aug;30(8):1646-55. doi: 10.1097/HJH.0b013e328355860e.

PMID:
22728908
9.

Alpha-lipoic acid improves endothelial dysfunction in patients with subclinical hypothyroidism.

G D X, J H P, H L S, L S Z.

Exp Clin Endocrinol Diabetes. 2010 Oct;118(9):625-9. doi: 10.1055/s-0029-1237702. Epub 2010 Feb 16.

PMID:
20162509
10.

Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone.

Derosa G, Fogari E, D'Angelo A, Cicero AF, Salvadeo SA, Ragonesi PD, Ferrari I, Gravina A, Fassi R, Fogari R.

J Clin Pharm Ther. 2007 Jun;32(3):261-8.

PMID:
17489878
11.

Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension.

Koh KK, Han SH, Chung WJ, Ahn JY, Jin DK, Kim HS, Park GS, Kang WC, Ahn TH, Shin EK.

Am J Cardiol. 2004 Jun 1;93(11):1432-5, A10.

PMID:
15165934
12.

Effects of AT1 receptor antagonism with candesartan on endothelial function in patients with hypertension and coronary artery disease.

Perrone-Filardi P, Corrado L, Brevetti G, Silvestro A, Dellegrottaglie S, Cafiero M, Caiazzo G, Petretta A, Maglione A, Monda C, Guerra G, Marzano A, Cesarano P, Gargiulo P, Chiariello M.

J Clin Hypertens (Greenwich). 2009 May;11(5):260-5.

PMID:
19534023
13.

Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha.

Derosa G, Cicero AF, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Ferrari I, Gravina A, Fogari R.

Hypertens Res. 2006 Nov;29(11):849-56.

PMID:
17345784
15.

α-lipoic acid can improve endothelial dysfunction in subjects with impaired fasting glucose.

Xiang G, Pu J, Yue L, Hou J, Sun H.

Metabolism. 2011 Apr;60(4):480-5. doi: 10.1016/j.metabol.2010.04.011. Epub 2011 Jan 20.

PMID:
21255807
16.

Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes.

Sowers JR, Neutel JM, Saunders E, Bakris GL, Cushman WC, Ferdinand KC, Ofili EO, Weber MA; INCLUSIVE Investigators.

J Clin Hypertens (Greenwich). 2006 Jul;8(7):470-80.

17.

Montelukast and irbesartan ameliorate metabolic and hepatic disorders in fructose-induced metabolic syndrome in rats.

Ibrahim MA, Amin EF, Ibrahim SA, Abdelzaher WY, Abdelrahman AM.

Eur J Pharmacol. 2014 Feb 5;724:204-10. doi: 10.1016/j.ejphar.2013.12.024. Epub 2013 Dec 24.

PMID:
24370493
19.

Pharmacodynamic effects of orally administered dexlipotam on endothelial function in type 2-diabetic patients.

Vossler S, Füllert S, Schneider F, Haak E, Haak T, Samigullin R, Tritschler H, Tooke JE, Konrad T.

Int J Clin Pharmacol Ther. 2007 Jul;45(7):385-93.

PMID:
17725245
20.

Supplemental Content

Support Center